Clinical Roundup Patients in Nepal experience substantial delays when accessing cancer care, study finds December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA grants 501(k) clearance for Vanquish System for prostate tissue ablation in intermediate risk prostate cancer December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves durvalumab + FLOT for resectable gastric or gastroesophageal junction adenocarcinoma December 05, 2025Vol.51 No.44
Drugs & Targets EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma December 05, 2025Vol.51 No.44
Drugs & Targets Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research December 05, 2025Vol.51 No.44
Conversation with The Cancer Letter Shane Jacobson talks about his to-do list for ACSBoost research, forge closer ties with cancer centers, launch an all-out campaign for resources November 21, 2025Vol.51 No.43
Guest Editorial My introduction to, and lessons learned from, Rick Pazdur November 21, 2025Vol.51 No.43By Mikkael A. Sekeres
Cancer Policy Trump cuts disrupted 383 clinical trials, affecting 74,000 trial participants November 21, 2025Vol.51 No.43By Jacquelyn Cobb
